Founded in 2010 in Nancy, France, QUIPMENT provides CROs and Sponsors with all the equipment solutions necessary to conduct their clinical trials. QUIPMENT ensures the availability, reliability and quality of the equipment delivered for clinical trials, in order to keep investigational sites fully operational throughout the entire duration of the clinical study

QUIPMENT is a leading player in the fast-growing clinical trial equipment solutions market, as sponsors and CROs increasingly rely on specialist players in response to the growing complexity of clinical trial protocols, regulations, and logistics. QUIPMENT’s unique and circular model, spanning sourcing, logistics, regulatory compliance, technical expertise, maintenance and end-of-study recovery and reprocessing, reduces operational and administrative burden for CROs and Sponsors, while supporting the decarbonization of the drug development value chain. The company, both a mission-driven company and B Corp certified, places sustainability and responsible growth at the heart of its operations. With more than 200 people, QUIPMENT operates from its Technical Service Centers in France, the United States and Japan to support the delivery of clinical trial equipment solutions to more than 110 countries worldwide

Céline GERVAIS, CEO of QUIPMENT commented "We are pleased to welcome SAGARD NEWGEN as a new strategic partner. Their strong sector expertise and international network combined with the values we share - high standards, customer-centricity and sustainability - make them the right partner to support us in our growth. Together, we will dedicate our efforts to promoting a site equipment solutions model for clinical trials designed to meet the growing demand for flexibility, while ensuring operational excellence and circularity across the clinical trials value chain"

Agnès HUYGHUES DESPOINTES and Bérangère BARBE, Partners at SAGARD NEWGEN added "We are very proud to partner with QUIPMENT’s best-in-class management team at this new stage of the company’s development. In just over a decade, QUIPMENT has become a market reference through relentless customer focus and uncompromising quality. It is a privilege to support a company widely recognized for its operational excellence, which delivers clear value to its clients by measurably easing logistical, regulatory and administrative burdens. QUIPMENT stands out with a truly differentiated value proposition, and we look forward to actively supporting the company and the management team to bolster QUIPMENT’S growth"

Michaël CHICHEPORTICHE, Managing Partner at ADVISO PARTNERS added "AGARD NEWGEN’s strategic minority investment in QUIPMENT is expected to enable the Group to further strengthen its position as the global leader in its market and accelerate its international expansion. We are very proud to have supported visionary founders and an outstanding management team, led by Céline GERVAIS, throughout their strategic thinking and this project. The Group’s distinctive growth trajectory, operational excellence, and sustainability strategy—embedded in its DNA—make QUIPMENT the benchmark and driving force in its market. This new transaction in the healthcare sector demonstrates ADVISO PARTNERS’ ability to deliver truly tailor-made solutions for its clients, helping them turn their ambitions into reality"